XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Income Statement [Abstract]        
Net sales $ 638,476 $ 681,110 $ 1,249,296 $ 1,357,954
Cost of goods sold 283,357 318,627 568,211 633,054
Gross profit 355,119 362,483 681,085 724,900
Selling, general and administrative expense 194,719 207,824 409,602 433,377
Research and Development Expense 58,904 65,042 125,279 139,993
Segment profit (loss) 101,496 89,617 146,204 151,530
Interest expense 12,264 12,343 24,541 24,680
Foreign exchange (gains) losses, net (1,699) (1,253) (3,653) (3,600)
Marketable Securities, Unrealized (Gain) Loss 2,895,355 1,595,442 2,473,178 1,612,967
Other Nonoperating Income (Expense) 18,143 16,488 52,659 66,919
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (2,786,281) (1,500,427) (2,295,203) (1,415,598)
(Provision) benefit for income taxes 620,795 338,176 513,633 322,309
Net income attributable to Bio-Rad $ (2,165,486) $ (1,162,251) $ (1,781,570) $ (1,093,289)
Basic earnings per share:        
Net income per share basic attributable to Bio-Rad $ (76.26) $ (39.59) $ (62.61) $ (37.09)
Weighted average common shares - basic 28,395 29,355 28,457 29,475
Diluted earnings per share:        
Net income per share diluted attributable to Bio-Rad $ (76.26) $ (39.59) $ (62.61) $ (37.09)
Weighted average common shares - diluted 28,395 29,355 28,457 29,475